PMID- 11286313
OWN - NLM
STAT- MEDLINE
DCOM- 20010719
LR  - 20200225
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 24
IP  - 3 Suppl
DP  - 2001 Mar
TI  - Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined 
      role in coronary interventions?
PG  - I8-11
AB  - Management strategies for acute coronary syndromes (ACS) are making increasing 
      use of both low-molecular-weight heparins (LMWHs) and glycoprotein (GP) IIb/IIIa 
      inhibitors. To date, however, relatively few studies have assessed the clinical 
      potential of these two classes of agents in combination. There are theoretical 
      grounds to expect LMWHs to be more effective than unfractionated heparin (UFH) in 
      combination with GP IIb/IIIa inhibitors, since UFH, but not LMWH, activates 
      platelets. The antiplatelet effects of GP IIb/IIIa inhibitors are therefore 
      likely to be both more potent and more predictable when combined with LMWH. A 
      recent study in more than 100 patients has demonstrated that a combination of 
      dalteparin and the GP IIb/IIIa inhibitor abciximab provided effective 
      anticoagulation in patients undergoing percutaneous coronary intervention (PCI), 
      without causing significant bleeding or adverse events. Similar results were 
      demonstrated in the National Investigators Collaborating on Enoxaparin (NICE-4) 
      study using a combination of abciximab and enoxaparin in patients undergoing PCI. 
      Of importance is the fact that there were no cases of severe thrombocytopenia in 
      either LMWH study, although this is a recognized potential complication when UFH 
      and abciximab are used in combination. Further studies are now warranted to 
      confirm the efficacy of LMWH and GP IIb/IIIa inhibitors in combination, both for 
      PCI and medical stabilization.
FAU - Fry, E T
AU  - Fry ET
AD  - St. Vincent Hospital, The Care Group, LLC, Indiana Heart Institute, Indianapolis 
      46260, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
SB  - IM
MH  - Angina, Unstable/*drug therapy
MH  - Anticoagulants/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Platelet Glycoprotein GPIIb-IIIa Complex/*therapeutic use
MH  - Syndrome
MH  - *Thrombolytic Therapy
PMC - PMC6654834
EDAT- 2001/04/05 10:00
MHDA- 2001/07/27 10:01
PMCR- 2009/02/03
CRDT- 2001/04/05 10:00
PHST- 2001/04/05 10:00 [pubmed]
PHST- 2001/07/27 10:01 [medline]
PHST- 2001/04/05 10:00 [entrez]
PHST- 2009/02/03 00:00 [pmc-release]
AID - CLC4960241304 [pii]
AID - 10.1002/clc.4960241304 [doi]
PST - ppublish
SO  - Clin Cardiol. 2001 Mar;24(3 Suppl):I8-11. doi: 10.1002/clc.4960241304.